Release of proinflammatory mediators and expression of proinflammatory adhesion molecules by endothelial progenitor cells. 2009

Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
Univ. of Chicago, Pritzker School of Medicine, 5841 South Maryland Ave, Mail-Code 6080, Chicago, IL 60637, USA.

Cell therapy with endothelial progenitor cells (EPCs) is an emerging therapeutic option to promote angiogenesis or endothelial repair. Although the release of angiogenic paracrine factors is known to contribute to their therapeutic effect, little is known about their release of proinflammatory factors and expression of proinflammatory adhesion molecules. "Early" EPCs and "late" EPCs were isolated from human peripheral blood and their release of chemokines and thromboinflammatory mediators as well as their expression of the proinflammatory adhesion molecules was assessed at baseline and with stimulation. The effect of simvastatin on monocyte chemoattractant protein-1 (MCP-1) secretion by late EPCs from patients with vascular disease was also evaluated. All groups of EPCs released chemokines and thromboinflammatory mediators. Early EPCs primarily released thromboinflammatory mediators such as tissue factor (0.5 +/- 0.1 ng/million cells, P < 0.05), whereas adult late EPCs primarily released chemokines such as MCP-1 (287 +/- 98 ng/million cells, P < 0.05). Stimulation with tumor necrosis factor (TNF)-alpha augmented the expression of proinflammatory adhesion molecules and paracrine factors by all EPC subtypes. The release of MCP-1 by late EPCs was markedly reduced by simvastatin treatment of the cells. All EPC subtypes expressed proinflammatory paracrine factors and adhesion molecules involved in atherosclerosis. Future clinical studies should therefore not only assess the efficacy of EPCs but also monitor inflammatory activation following EPC transplantation in patients. Pharmacological modulation of EPCs before and after transplantation may represent a novel approach to improve their safety.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015815 Cell Adhesion Molecules Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis. Cell Adhesion Molecule,Intercellular Adhesion Molecule,Intercellular Adhesion Molecules,Leukocyte Adhesion Molecule,Leukocyte Adhesion Molecules,Saccharide-Mediated Cell Adhesion Molecules,Saccharide Mediated Cell Adhesion Molecules,Adhesion Molecule, Cell,Adhesion Molecule, Intercellular,Adhesion Molecule, Leukocyte,Adhesion Molecules, Cell,Adhesion Molecules, Intercellular,Adhesion Molecules, Leukocyte,Molecule, Cell Adhesion,Molecule, Intercellular Adhesion,Molecule, Leukocyte Adhesion,Molecules, Cell Adhesion,Molecules, Intercellular Adhesion,Molecules, Leukocyte Adhesion
D016209 Interleukin-8 A member of the CXC chemokine family that plays a role in the regulation of the acute inflammatory response. It is secreted by variety of cell types and induces CHEMOTAXIS of NEUTROPHILS and other inflammatory cells. CXCL8 Chemokine,Chemokine CXCL8,Chemotactic Factor, Macrophage-Derived,Chemotactic Factor, Neutrophil, Monocyte-Derived,IL-8,Neutrophil-Activating Peptide, Lymphocyte-Derived,Neutrophil-Activating Peptide, Monocyte-Derived,AMCF-I,Alveolar Macrophage Chemotactic Factor-I,Anionic Neutrophil-Activating Peptide,Chemokines, CXCL8,Chemotactic Factor, Neutrophil,Granulocyte Chemotactic Peptide-Interleukin-8,IL8,Monocyte-Derived Neutrophil Chemotactic Factor,Neutrophil Activation Factor,Alveolar Macrophage Chemotactic Factor I,Anionic Neutrophil Activating Peptide,CXCL8 Chemokines,CXCL8, Chemokine,Chemokine, CXCL8,Chemotactic Factor, Macrophage Derived,Chemotactic Peptide-Interleukin-8, Granulocyte,Granulocyte Chemotactic Peptide Interleukin 8,Interleukin 8,Lymphocyte-Derived Neutrophil-Activating Peptide,Macrophage-Derived Chemotactic Factor,Monocyte-Derived Neutrophil-Activating Peptide,Neutrophil Activating Peptide, Lymphocyte Derived,Neutrophil Activating Peptide, Monocyte Derived,Neutrophil Chemotactic Factor,Neutrophil-Activating Peptide, Anionic,Peptide, Anionic Neutrophil-Activating
D017493 Leukocyte Common Antigens High-molecular weight glycoproteins uniquely expressed on the surface of LEUKOCYTES and their hemopoietic progenitors. They contain two FIBRONECTIN TYPE III DOMAINS and possess cytoplasmic protein tyrosine phosphatase activity, which plays a role in intracellular signaling from the CELL SURFACE RECEPTORS. Leukocyte common antigens occur as multiple isoforms that result from alternative mRNA splicing and differential usage of three exons. Antigens, CD45,CD45 Antigens,CD45R Antigens,CD45RA Antigens,CD45RO Antigens,Protein Tyrosine Phosphatase, Receptor Type, C,2H4 Antigens,B220 Antigen,B220 Antigens,CD45 Antigen,CD45R0 Antigens,CD45RB Antigens,CD45RCAntigens,L-CA Antigens,Leukocyte Common Antigen,T200 Antigens,Antigen, B220,Antigen, CD45,Antigen, Leukocyte Common,Antigens, 2H4,Antigens, B220,Antigens, CD45R,Antigens, CD45R0,Antigens, CD45RA,Antigens, CD45RB,Antigens, CD45RO,Antigens, L-CA,Antigens, Leukocyte Common,Antigens, T200,L CA Antigens
D042783 Endothelial Cells Highly specialized EPITHELIAL CELLS that line the HEART; BLOOD VESSELS; and lymph vessels, forming the ENDOTHELIUM. They are polygonal in shape and joined together by TIGHT JUNCTIONS. The tight junctions allow for variable permeability to specific macromolecules that are transported across the endothelial layer. Capillary Endothelial Cells,Lymphatic Endothelial Cells,Vascular Endothelial Cells,Capillary Endothelial Cell,Cell, Capillary Endothelial,Cell, Endothelial,Cell, Lymphatic Endothelial,Cell, Vascular Endothelial,Cells, Capillary Endothelial,Cells, Endothelial,Cells, Lymphatic Endothelial,Cells, Vascular Endothelial,Endothelial Cell,Endothelial Cell, Capillary,Endothelial Cell, Lymphatic,Endothelial Cell, Vascular,Endothelial Cells, Capillary,Endothelial Cells, Lymphatic,Endothelial Cells, Vascular,Lymphatic Endothelial Cell,Vascular Endothelial Cell

Related Publications

Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
October 2010, International journal of clinical and experimental medicine,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
February 1996, The American journal of physiology,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
March 1998, Journal of leukocyte biology,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
March 1996, The American journal of physiology,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
April 2003, Inflammation,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
January 1993, Virchows Archiv. A, Pathological anatomy and histopathology,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
October 2002, The Journal of pathology,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
November 1996, Microbial pathogenesis,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
March 1997, Obstetrics and gynecology,
Yanmin Zhang, and David A Ingram, and Michael P Murphy, and M Reza Saadatzadeh, and Laura E Mead, and Daniel N Prater, and Jalees Rehman
November 1998, Rinsho byori. The Japanese journal of clinical pathology,
Copied contents to your clipboard!